Skip to content

Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis

Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis in France in the Entire Population of the RSI (Other Branches of the Universal Healthcare Insurance Agency)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01566851
Enrollment
7000
Registered
2012-03-29
Start date
2012-06-01
Completion date
2013-11-01
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Check-up in Patients With Rheumatoid Arthritis

Brief summary

Introduction Cardiovascular diseases are the first cause of death in rheumatoid arthritis (RA). In 2010, EULAR Standing Committee for Clinical Affairs provides 10 recommendations for cardiovascular risk management in patients with rheumatoid arthritis, including a cardiovascular risk assessment annually. The goal of this study is to evaluate the application of EULAR recommendations in real life in patients with RA in the french population. Inclusion criteria: all patients over 18 years old with rheumatoid arthritis treated with at least one DMARDS and/or biologic therapy, affiliated to the RSI (regime social des independents which correspond to other branches of the universal healthcare insurance agency). Non inclusion criteria: patients declared as rheumatoid arthritis without DMARDS or biologic therapy or treated with steroids alone. The following analysis will be performed on the whole database of the RSI, without name identification. Evaluation criteria: at least once a years the prescription of at least one of the following items use in the evaluation of the cardiovascular risk factors: lipides dosage, glycemia, HbA1C, stress test, Carotid ultra-sonography, coronary or lower limbs arteriography, heart ultra-sonography, cardiology clinic, endocrinology clinic. This evaluation will be done on the whole national population of RSI for the year 2011 (01/01/2011 - 31/12/2011). On a subgroup of patients from the region "Provence Alpes Côte d'Azur", the investigators will analyze the year 2009, and compare to year 2011, to evaluate the impact of theses recommendations.

Interventions

OTHERCardiovascular check-up

Cardiovascular check-up once a year in patients with rheumatoid arthritis

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years, affiliated to RSI, with rheumatoid arthritis treated with at least one DMARDS and/or biologic therapy

Exclusion criteria

* patients under 18 years * Patients declared as rheumatoid arthritis without DMARDS or biologic therapy or treated with steroids alone

Design outcomes

Primary

MeasureTime frameDescription
the following items use in the evaluation of the cardiovascular risk factorsat time = 2 yearsAt least once a years the prescription of at least one of the following items use in the evaluation of the cardiovascular risk factors: * Lipides dosage * Glycemia * HbA1C * Stress test * Carotid ultra-sonography * Coronary or lower limbs arteriography * Heart ultra-sonography * Cardiology clinic * Endocrinology clinic

Secondary

MeasureTime frameDescription
the following items use in the evaluation of the cardiovascular risk factors on the sub populationt=0 and t=2 yearsThe same criteria of primary criteria but on the sub population of Povence Alpes Cote-d'Azur region a comparison of these criteria in 2009 (before EULAR recommendations ) and in 2011 (after EULAR recommendations)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORLiana EULLER-ZIEGLER, PU-PH

Centre Hospitalier Universitaire de Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026